Further study showed that the efficacy of combined YTHDF1 knockdown and anti-PD-L1 treatment was quite good, superior to that of single agent control group, and combining m6A with immune checkpoint inhibitor (ICI) treatment is promising in tumor therapy. This evidence concerns the gene CD274 and neoplasm.